Viveve Medical Priced, Nasdaq: VIVE

Commercializing a non-invasive medical system that reverses vaginal laxity.

Industry: Health Care

Latest Trade: $4.98 0.00 (0.0%)

First Day Return: -1.0%

Return from IPO: -0.4%

Industry: Health Care

Viveve designs, develops, manufactures and markets the Viveve System, a medical device for the non-invasive treatment of vaginal introital laxity. Women can develop vaginal laxity for a number of reasons, including aging, genetic predisposition, lifestyle, and/or the trauma of natural childbirth. Vaginal laxity can often cause decreased sexual function and satisfaction in women, yet most surveyed physicians who practice obstetrics and gynecology and urogynecologists recognize that it is an underreported, yet bothersome, medical condition that impacts relationship happiness as well as sexual function. Currently, few medical treatments are available to effectively treat vaginal laxity. The most widely prescribed treatments include Kegel exercises, although, to our knowledge, there is no validated evidence indicating that Kegel exercises improve vaginal laxity, and surgical procedures, which are not only invasive and expensive but sometimes lead to worse outcomes as a result of scarring.
more less
IPO News for Viveve Medical
more
IPO Data
IPO File Date 04/19/2016
Offer Price $5.00
Price Range $5.00 - $5.00
Offer Shares (mm) 2.7
Deal Size ($mm) $14
IPO Data
IPO Date 06/14/2016
Offer Price $5.00
Price Range $5.00 - $5.00
Offer Shares (mm) 2.7
Deal Size ($mm) $14
Underwriters
more
Company Data
Headquarters Sunnyvale, CA
Founded 2005
Employees 23
Website www.viveve.com